Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Teva
Federal Trade Commission
Fish and Richardson
Cerilliant
Citi
Harvard Business School
Baxter

Generated: August 14, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207042

« Back to Dashboard

NDA 207042 describes NEOSTIGMINE METHYLSULFATE, which is a drug marketed by Amneal Pharms Co, Amphastar Pharms Inc, Dr Reddys Labs Ltd, Eurohlth Intl Sarl, Fresenius Kabi Usa, Luitpold Pharms Inc, and Par Sterile Products, and is included in seven NDAs. It is available from ten suppliers. Additional details are available on the NEOSTIGMINE METHYLSULFATE profile page.

The generic ingredient in NEOSTIGMINE METHYLSULFATE is neostigmine methylsulfate. There are eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the neostigmine methylsulfate profile page.
Summary for 207042
Tradename:NEOSTIGMINE METHYLSULFATE
Applicant:Eurohlth Intl Sarl
Ingredient:neostigmine methylsulfate
Patents:0
Therapeutic Class:Antimyasthenic Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 207042
Mechanism of ActionCholinesterase Inhibitors
Medical Subject Heading (MeSH) Categories for 207042
Suppliers and Packaging for NDA: 207042
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NEOSTIGMINE METHYLSULFATE neostigmine methylsulfate SOLUTION;INTRAVENOUS 207042 ANDA West-Ward Pharmaceuticals Corp. 0641-6149 N 0641-6149-10
NEOSTIGMINE METHYLSULFATE neostigmine methylsulfate SOLUTION;INTRAVENOUS 207042 ANDA West-Ward Pharmaceuticals Corp. 0641-6149 N 0641-6149-25

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength5MG/10ML (0.5MG/ML)
Approval Date:Dec 28, 2015TE:APRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength10MG/10ML (1MG/ML)
Approval Date:Dec 28, 2015TE:APRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Teva
Cantor Fitzgerald
Argus Health
Express Scripts
AstraZeneca
Citi
Chinese Patent Office
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.